No Data
No Data
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $72
PTC Therapeutics Price Target Raised to $78.00/Share From $72.00 by JP Morgan
PTC Therapeutics Is Maintained at Overweight by JP Morgan
Citi Initiates PTC Therapeutics(PTCT.US) With Sell Rating, Announces Target Price $50
PTC Appoints Trac Pham to Board of Directors
PTC Therapeutics (NASDAQ:PTCT) Shareholder Returns Have Been Favorable, Earning 74% in 1 Year